Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002629878 | SCV003523838 | uncertain significance | Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 3 | 2022-02-06 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with NCF4-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.002%). This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 316 of the NCF4 protein (p.His316Tyr). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004654164 | SCV005145238 | uncertain significance | not specified | 2024-03-15 | criteria provided, single submitter | clinical testing | The c.946C>T (p.H316Y) alteration is located in exon 8 (coding exon 8) of the NCF4 gene. This alteration results from a C to T substitution at nucleotide position 946, causing the histidine (H) at amino acid position 316 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |